×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ADXS

Advaxis Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.31 million shs
Average Volume
607,996 shs
Market Capitalization
$9.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Advaxis MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Advaxis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.33 out of 5 stars


Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

Advaxis logo

About Advaxis (NASDAQ:ADXS) Stock

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

ADXS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADXS
Employees
N/A
Year Founded
N/A

Company Calendar

Today
7/03/2022
Fiscal Year End
10/31/2022

Profitability

Net Income
$-17.86 million
Pretax Margin
-873.85%

Debt

Sales & Book Value

Annual Sales
$3.24 million
Book Value
$0.27 per share

Miscellaneous

Free Float
145,201,000
Market Cap
$9.03 million
Optionable
Not Optionable
Beta
2.15














Advaxis Frequently Asked Questions

Who are Advaxis' key executives?

Advaxis' management team includes the following people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 58, Pay $625.4k)
  • Mr. Igor Gitelman CPA, CPA, M.B.A., MBA, Chief Accounting Officer, Interim CFO & VP of Fin. (Age 46, Pay $297.87k)
  • Dr. Andres A. Gutierrez M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 61, Pay $472.03k)

What other stocks do shareholders of Advaxis own?

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Advaxis make?

Advaxis (NASDAQ:ADXS) has a market capitalization of $0.00 and generates $3.24 million in revenue each year. The company earns $-17.86 million in net income (profit) each year or ($0.10) on an earnings per share basis.

How can I contact Advaxis?

Advaxis' mailing address is 9 DEER PARK DRIVE SUITE K-1, MONMOUTH JUNCTION NJ, 08852. The official website for Advaxis is www.advaxis.com. The company can be reached via phone at 609 452 9813, via email at ir@advaxis.com, or via fax at 609-452-9818.

This page (NASDAQ:ADXS) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.